Development and implementation of a novel immune thrombocytopenia bleeding score for dogs by Makielski, Kelly M. et al.
Veterinary Diagnostic and Production Animal
Medicine Publications
Veterinary Diagnostic and Production Animal
Medicine
2018
Development and implementation of a novel
immune thrombocytopenia bleeding score for
dogs
Kelly M. Makielski
Iowa State University
Marjory B. Brooks
Cornell University
Chong Wang
Iowa State University, chwang@iastate.edu
Jonah N. Cullen
Iowa State University
Annette M. O'Connor
Iowa State University, oconnor@iastate.edu
See next page for additional authors
Follow this and additional works at: https://lib.dr.iastate.edu/vdpam_pubs
Par  of th Small or Comp nion Animal Medicine Commons, Statistical Methodology
Commons, Veterinary Microbiology and Immunobiology Commons, and the Veterinary Preventive
Medicine, Epidemiology, and Public Health Commons
The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/
vdpam_pubs/106. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Veterinary Diagnostic and Production Animal Medicine at Iowa State University Digital
Repository. It has been accepted for inclusion in Veterinary Diagnostic and Production Animal Medicine Publications by an authorized administrator
of Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu.
Development and implementation of a novel immune thrombocytopenia
bleeding score for dogs
Abstract
Background
A method of quantifying clinical bleeding in dogs with immune thrombocytopenia (ITP) is needed because
ITP patients have variable bleeding tendencies that inconsistently correlate with platelet count. A scoring
system will facilitate patient comparisons and allow stratification based on bleeding severity in clinical trials.
Hypothesis/Objectives
To develop and evaluate a bleeding assessment tool for dogs, and a training course for improving its consistent
implementation.
Animals
Client‐owned dogs (n = 61) with platelet counts <50,000/μL; 34 classified as primary ITP, 17 as secondary
ITP, and 10 as non‐ITP.
Methods
A novel bleeding assessment tool, DOGiBAT, comprising bleeding grades from 0 (none) to 2 (severe) at 9
anatomic sites, was developed. Clinicians and technicians completed a training course and quiz before scoring
thrombocytopenic patients. The training course was assessed by randomizing student volunteers to take the
quiz with or without prior training. A logistic regression model assessed the association between training and
quiz performance. The correlation of DOGiBAT score with platelet count and outcome measures was
assessed in the thrombocytopenic dogs.
Results
Clinicians and technicians consistently applied the DOGiBAT, correctly scoring all quiz cases. The odds of
trained students answering correctly were higher than those of untrained students (P < .0001). In clinical
cases, DOGiBAT score and platelet count were inversely correlated (rs = −0.527, P < .0001), and DOGiBAT
directly correlated with transfusion requirements (rs = 0.512, P < .0001) and hospitalization duration (rs =
0.35, P = .006).
Conclusions and Clinical Importance
The DOGiBAT and assessment quiz are simple tools to standardize evaluation of bleeding severity. With
further validation, the DOGiBAT may provide a clinically relevant metric to characterize ITP severity and
monitor response in treatment trials.
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Background: A method of quantifying clinical bleeding in dogs with immune thrombocytopenia
(ITP) is needed because ITP patients have variable bleeding tendencies that inconsistently correlate
with platelet count. A scoring system will facilitate patient comparisons and allow stratification
based on bleeding severity in clinical trials.
Hypothesis/Objectives: To develop and evaluate a bleeding assessment tool for dogs, and a train-
ing course for improving its consistent implementation.
Animals: Client-owned dogs (n561) with platelet counts <50,000/lL; 34 classified as primary
ITP, 17 as secondary ITP, and 10 as non-ITP.
Methods: A novel bleeding assessment tool, DOGiBAT, comprising bleeding grades from 0 (none)
to 2 (severe) at 9 anatomic sites, was developed. Clinicians and technicians completed a training
course and quiz before scoring thrombocytopenic patients. The training course was assessed by
randomizing student volunteers to take the quiz with or without prior training. A logistic regression
model assessed the association between training and quiz performance. The correlation of DOGi-
BAT score with platelet count and outcome measures was assessed in the thrombocytopenic dogs.
Results: Clinicians and technicians consistently applied the DOGiBAT, correctly scoring all quiz
cases. The odds of trained students answering correctly were higher than those of untrained stu-
dents (P< .0001). In clinical cases, DOGiBAT score and platelet count were inversely correlated
(rs520.527, P< .0001), and DOGiBAT directly correlated with transfusion requirements
(rs50.512, P< .0001) and hospitalization duration (rs50.35, P5 .006).
Conclusions and Clinical Importance: The DOGiBAT and assessment quiz are simple tools to
standardize evaluation of bleeding severity. With further validation, the DOGiBAT may provide a
clinically relevant metric to characterize ITP severity and monitor response in treatment trials.
K E YWORD S
bleeding scale, daily canine bleeding assessment tool, immune-mediated thrombocytopenic pur-
pura, platelets
Abbreviations: DOGiBAT, daily canine bleeding assessment tool; IBLS, ITP bleeding scale; ITP, immune thrombocytopenia; NI, nonimmune; PI, primary immune; SI,
secondary immune
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1 | INTRODUCTION
Immune thrombocytopenia (ITP) is a common cause of severe throm-
bocytopenia in dogs.1 It occurs when antiplatelet antibodies bound to
the platelet surface lead to clearance and premature platelet destruc-
tion by the reticuloendothelial system.2,3 Although ITP causes throm-
bocytopenia, not all dogs with ITP develop signs of hemorrhage and
platelet count does not consistently predict bleeding risk or mortality.4
Human ITP patients also have been shown to have heterogeneous
bleeding phenotypes. One study in the human literature reported no
association between platelet count and bleeding severity in patients
with severe thrombocytopenia (platelet count<30,000/lL).5
Immunosuppressive doses of glucocorticoids are the current first-
line treatment for dogs with ITP, but few evidence-based guidelines exist
to dictate the timing or choice of adjunctive, second-line therapies.4,6,7
Several studies have used platelet recovery as the main indicator of
response to treatment.6,8,9 However, treatment to attain a target platelet
count has the potential to lead to over-treatment (ie, higher drug
dosages and addition of adjunctive immunosuppressants that may not
provide additional benefit in preventing or controlling bleeding). Cortico-
steroids and combined immunosuppressive drug treatment carry risks
including gastrointestinal ulceration,10 hepatotoxicity,11 secondary
infections,12–14 and potential hypercoagulability.15 Because platelet
count alone does not reliably predict clinically relevant bleeding in canine
or human ITP patients,4,5 additional clinical and laboratory metrics for
objectively gauging bleeding severity are needed to minimize the risk of
over-treatment for an individual patient and to stratify patients for pro-
spective clinical studies. A bleeding score metric would help to objec-
tively assess efficacy of adjunctive therapies in multicenter clinical trials,
stratify patients according to their bleeding severity, and identify labora-
tory variables that predict or correlate with bleeding severity.
Our primary objective was to develop a novel ITP bleeding assess-
ment tool for dogs or “DOGiBAT” to allow more consistent and stand-
ardized quantification of bleeding severity in dogs with ITP. Other
study objectives were to assess a training course designed to instruct
users of the DOGiBAT on its correct implementation, and to apply the
DOGiBAT in clinical cases of canine thrombocytopenia to assess the
relationship between DOGiBAT and platelet count and as a preliminary
evaluation of the relationship between DOGiBAT and patient outcome.
Dogs with platelet counts<50,000/lL of any underlying etiology were
included in this pilot project. We hypothesized that the use of the
DOGiBAT would allow for consistent bleeding severity scoring among
clinicians, and that a training course would improve less clinically expe-
rienced users’ (veterinary students’) ability to correctly assign bleeding
severity scores. We also hypothesized that in clinical cases of thrombo-
cytopenia in dogs, DOGiBAT score and platelet count would be inver-
sely correlated, but that this relationship would be lost in severely
thrombocytopenic dogs (platelet counts<30,000/lL). For these cases,
no consistent association between platelet count and DOGiBAT score
would exist, as described for people with ITP evaluated using a compa-
rable scoring system,5 and based on the observed bleeding heterogene-
ity of severely thrombocytopenic ITP dogs.1,3,4
2 | MATERIALS AND METHODS
2.1 | Development of DOGiBAT, training course, and
case-based quiz
A novel daily bleeding assessment tool for dogs, the DOGiBAT, was
developed for dogs with ITP (Table 1). This tool was modeled after a
scoring system designed for human ITP patients, the ITP Bleeding Scale
(IBLS).5 The DOGiBAT comprised 9 different anatomic sites (cutaneous,
TABLE 1 Novel canine daily bleeding score assessment tool, DOGiBAT, developed for canine ITP
Bleeding grade
Site 0 1 2
Skin No Petechiae/ecchymoses single site Petechiae/ecchymoses >1 anatomic site
Catheter/venipuncture/
other cutaneous bleed
No Self-limiting and <5 minutes >5 minutes and/or intervention to control
Oral mucosa No Petechiae Frank hemorrhage
Intraocular No Funduscopic Hyphema
Epistaxis No Unilateral and <5 minutes Bilateral or >5 minutes
Gastrointestinal Occult blood (–);
(Hema-chekTM,
Siemans Healthcare
Diagnostics Inc.,
Tarrytown, New York)
Occult blood (1);
(Hema-chekTM,
Siemans Healthcare
Diagnostics Inc.)
Hematemesis, hematochezia, melena
Urinary No Microscopic (dipstick) Macroscopic
Pulmonary hemorrhage
(suspected/observed)
No N/A Yes
Intracranial hemorrhage
(suspected/observed)
No N/A Yes
Each anatomic site receives a grade of 0 (none), 1 (mild), or 2 (severe), as detailed above. The grades at each site are totaled to give a maximal DOGiBAT of 18.
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catheter or venipuncture bleeding, oral mucosa, intraocular, epistaxis,
gastrointestinal, urinary, pulmonary, and intracranial). Each anatomic
site was given a site-specific bleeding grade of 0 (none), 1 (mild), or 2
(severe), with the exception of pulmonary and intracranial, which were
given only grades of 0 (absent) or 2 (suspected/present).
A computer-based training course was developed to train users in
the application of the DOGiBAT to clinical cases. The training course
initially introduced the participant to general principles of scoring
within the DOGiBAT bleeding tool, and then provided pictures from
clinical patients demonstrating to the trainee the appearance of each
bleeding grade at each anatomic site. Sample slides demonstrating cor-
rect scoring of cutaneous hemorrhage are shown in Figure 1, and
the complete training course is available in Supporting Information
(Figure S1).
A case-based quiz set of still images also was developed, using
images from clinical cases. This case-based quiz was used to assess
users’ ability to correctly apply the DOGiBAT tool after they had com-
pleted the training course. We designed a standard case-based quiz to
allow for consistency over time and across multiple institutions. The
quiz provided the user with clinical case descriptions and images to
completely score 3 canine thrombocytopenic cases using the DOGi-
BAT. The complete quiz is available in the supplementary materials,
along with the quiz score sheet to record answers, and the answer key
to the quiz (Supporting Information Figures S2-S4).
2.2 | Study design
This study consisted of 3 phases, as outlined in Figure 2. In phase 1,
clinicians and technicians took the training course, after which they
completed a case-based quiz to assess their ability to correctly imple-
ment the DOGiBAT.
In phase 2, equal numbers of third and fourth year veterinary stu-
dent volunteers (n570) were randomized (https://www.randomizer.
org) to take the quiz with (n535) or without (n535) completing the
training course to assess the effectiveness of the training course. Vet-
erinary students were selected as representative of a pool of users
with a similar level of professional veterinary education. The study was
considered exempt by the Iowa State University Institutional Review
Board.
In phase 3, the clinicians who had received training on correct
implementation of the DOGiBAT in phase 1 applied the DOGiBAT
bleeding tool to clinical cases as part of a larger multicenter study of
thrombocytopenia in dogs. Canine patients presenting to Iowa State
University (ISU), Cornell University Hospital for Animals (CUHA), Cor-
nell University Veterinary Specialists (CUVS), and Veterinary Specialists
and Emergency Services (VSES), with body weight>3 kg and platelet
count<50,000/lL of any underlying etiology were enrolled with client
consent. Because the cause of thrombocytopenia was determined in
the course of diagnostic evaluation, dogs with immune and non-ITP
were enrolled for compilation of DOGiBAT scores, clinicopathologic
FIGURE 1 Sample slide from training course instructing the DOGiBAT user on how to correctly score cutaneous bleeding
FIGURE 2 Experimental design showing the 3 phases of this
study
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variables, and outcome measures. Cases were excluded if they had
received glucocorticoids for a period of>48 hours at the time of
enrollment or if they had received any other immunosuppressive thera-
pies. These cases were excluded to enroll a relatively homogeneous
population of dogs with newly diagnosed thrombocytopenia.
Enrolled thrombocytopenic dogs were classified into 3 subgroups
according to the underlying etiology of the thrombocytopenia, using a
classification scheme similar to 1 previously described.16 In brief, dogs
were classified into 1 of 3 subgroups as follows: Subgroup 1 (PI)—dogs
with primary ITP, in the absence of an underlying cause based on
diagnostic imaging and laboratory testing; Subgroup 2 (SI)—dogs with
secondary ITP due to identified neoplasia, drug treatment, or infectious
disease; and, Subgroup 3 (NI)—dogs with non-ITP, secondary to bone
marrow aplasia based on CBC or bone marrow examination or consump-
tive coagulopathy associated with an abnormal coagulation profile. Diag-
nostic testing and treatment decisions were at the discretion of the
attending clinician. After study completion and before undertaking data
analyses, case records were reviewed and classification was confirmed
by consensus among 3 of the authors (K.M. Makielski, D.N. LeVine, and
M.B. Brooks) based on all available diagnostic results.
All dogs were scored on admission with the DOGiBAT. The PI
cases enrolled at all institutions were scored daily using the DOGiBAT,
from time of enrollment until discharge from the hospital, death, or
euthanasia, or until a maximum of 7 days. The SI and NI cases were all
scored on day 1, with daily scoring until discharge only for cases
enrolled at ISU. The score sheet to record daily bleeding scores for clin-
ical cases of ITP using the DOGiBAT is available in the Supporting
Information (Figure S5). Platelet counts were obtained either as an
automated count on a hematology analyzer (ADVIA 2120, Siemens
Healthcare Diagnostics Inc, Tarrytown, New York) as part of a CBC or
as a manual platelet count. All automated counts were confirmed by
technician review of a blood smear. The study was approved by the
Institutional Animal Care and Use Committees of ISU and CUHA.
2.3 | Statistical analysis
Sample size calculations were performed using online resources (Open-
Epi, Atlanta, Georgia; http://www.stat.ubc.ca/~rollin/stats/ssize/b2.
html) to determine the number of students needed per group (students
with access to the training course and students who were not given
access to the training course) to detect a significant difference in
DOGiBAT quiz score with training. Pilot data was utilized from 10
untrained veterinary students who scored 3 cases (cluster size 30) with
a baseline correct response rate of 75%. Using independent samples,
an alpha50.05 and 80% power, the required sample size to detect a
significant difference (defined as a 20% increase in number of correct
scores) between the 2 groups was calculated. When sample sizes were
adjusted for clustering by students (ie, each student answered multiple
questions), and assuming an intraclass correlation of 0.75, the required
sample size was determined to be 35 students in the trained group and
35 students in the untrained group.
For data analysis of quiz-taker performance, bleeding grades were
converted to a 2-level outcome variable, where the response was
considered either correct (1) or incorrect (0). Quiz site scores were con-
sidered correct if they agreed with the investigators’ pre-specified clas-
sification. A logistic regression model was used to model factors
associated with the outcome (probability of being correct), while
adjusting for correlated responses from sites within cases [Statistical
Analysis System (SAS) 9.3, SAS Institute Inc, Cary, North Carolina]. The
explanatory variables of interest were training or not and grade level of
the student (third versus fourth year). Additionally, the interaction
between training and grade level was included. Case was used as a ran-
dom effect whenever appropriate to account for the dependency
among observations.
To assess the association between DOGiBAT score and platelet
count in the clinical phase of the study, a Spearman correlation coeffi-
cient was calculated for each anatomic site and for total DOGiBAT
score [Statistical Analysis System (SAS) 9.3, SAS Institute Inc]. Only
days that had both a platelet count and a DOGiBAT score performed
were included in this analysis. Automated platelet counts that were
reported as <10,000/lL or <20,000/lL were converted to 9,000/lL
and 19,000/lL, respectively, for data analysis. To compare admission
DOGiBAT scores and platelet counts among the 3 groups of dogs (PI,
SI, NI), Kruskal-Wallis tests were performed followed by pairwise com-
parisons with nonparametric Wilcoxon rank sum tests when differen-
ces among all 3 groups were identified. Assumptions of normality were
not made. P-values< .05 were considered significant.
Spearman correlation coefficients were calculated to assess the
associations between admission DOGiBAT score (at each anatomic site
and total DOGiBAT score) and outcome measures, and between admis-
sion platelet count and outcome measures. Outcome measures
assessed were transfusion requirements, duration of hospitalization
(days), and survival to discharge. For data analysis of outcome meas-
ures, transfusion requirements and survival to discharge each were
converted to a 2-level outcome variable. In the case of transfusion
requirements, the outcome was whether any volume of any blood
product(s) was administered during hospitalization (1) or no blood prod-
ucts were administered (0). For survival, the outcome was death or
euthanasia while hospitalized (0) or survival to discharge from the hos-
pital (1). Wilcoxon rank sum tests were performed to compare outcome
measures between PI dogs and non-PI dogs (SI and NI; Prism 6.0,
GraphPad Software Inc., La Jolla, CA). P-values< .05 were considered
significant.
3 | RESULTS
In the first phase of this project, clinicians (n513) and technicians
(n53) completed a case-based quiz after training. Clinicians consisted
of boarded-certified small animal specialists (n56), residents (n55), a
rotating intern (n51), and an internship-trained emergency veterinar-
ian (n51). Technicians were all licensed veterinary technicians.
Clinicians and technicians were able to correctly apply the DOGiBAT
after training, scoring 100% of responses correctly.
In the second phase of this project, 70 veterinary students were
administered the case-based quiz, after having been randomized to
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either receive the training course (n535) or no training (n535). Of
the students who received training, 17/35 were third year veterinary
students and 18/35 were fourth year veterinary students. Of the stu-
dents who received no training, 18/35 were third year veterinary stu-
dents and 17/35 were fourth year veterinary students. Student
enrollment was kept open for a period of 6 months. Therefore, stu-
dents taking the quiz were at various points of their third and fourth
years of veterinary school. Students who received training correctly
scored 86.1% (814/945) of responses, compared with only 78.2%
(739/945) of responses from students who did not receive training.
The odds of trained students giving correct answers were higher than
those of untrained students (P< .0001). Numbers and percentages of
correct scores from students with and without training at each ana-
tomic site are shown in Table 2. The anatomic site for which training
was most important for correct scoring was oral bleeding (82.9% [87/
105] with training; 47.6% [50/105] without training; P< .0001). Simi-
larly, correct scoring of ocular (75.2% [79/105] with training; 58.1%
[61/105] without training; P5 .01) and cutaneous bleeding (84.8%
[89/105] with training; 66.7% [70/105] without training; P5 .003)
were significantly improved by prior training. Regardless of training sta-
tus, fourth year students were better able to apply the DOGiBAT cor-
rectly (84.2% [796/945]) compared with third year students (80.1%
[757/945]; P5 .015). When analyzed separately, training benefited stu-
dents regardless of their class year, because training had a significant
effect on correct scoring in both the third year (P5 .02) and fourth
year (P< .0001) veterinary students.
In the third phase of this project, the clinicians (n513) trained in
phase 1 utilized the DOGiBAT for daily assessment of bleeding in a
multicenter cohort study of dogs with thrombocytopenia. Dogs
(n561) with platelet counts <50,000/lL, regardless of etiology, were
enrolled. Enrolled dogs consisted of 31 female dogs (50.8%; 30 spayed,
1 intact) and 30 male dogs (49.2%; 26 castrated, 4 intact). These dogs
were classified based on results of diagnostic testing as primary
immune (PI)-mediated (PI; 34/61; 55.7%), secondary immune (SI)-medi-
ated (SI; 17/61; 27.9%), or nonimmune-mediated (NI; 10/61; 16.4%).
Of the 34 dogs considered PI, this was the first presentation for 32 of
the dogs (94.1%), whereas 2/34 (5.9%) had prior treatment for ITP and
were presenting for disease relapse. On admission to the hospital, pla-
telet counts were significantly lower in the PI dogs (median, 9,500/lL;
range, 0–40,000/lL) than the SI dogs (median, 21,000/lL; range, 0–
44,000/lL; P5 .034) or NI dogs (median, 26,000/lL; range, 11,000–
44,000/lL; P5 .003; Figure 3A). Total DOGiBAT scores also were sig-
nificantly higher in the PI dogs on admission (median, 5; range, 0–12)
than in the SI dogs (median, 3; range, 0–12; P5 .021) or NI dogs
(median, 2; range, 0–10; P5 .01; Figure 3B). Admission platelet counts
(P5 .305) and admission DOGiBAT scores (P5 .239) were not signifi-
cantly different between the SI dogs and the NI dogs. The most com-
mon anatomic sites of bleeding on enrollment in the study were
cutaneous bleeding (38/61 [62.3%] of enrolled dogs), followed by oral
mucosa (31/61 [50.8%]), gastrointestinal (25/61 [41%]) and urinary
(25/61 [41%]). A significant negative correlation was found between
platelet count and DOGiBAT score in all dogs (rs520.527, P< .0001;
TABLE 2 Numbers and percentages of correct scores at each
anatomic site on a case-based quiz from students with and without
training
Trained Untrained
DOGiBAT site #/105 % #/105 % P-value
Skin 89 84.8 70 66.7 .003
Catheter, etc. 68 64.8 79 75.2 .115
Oral cavity 87 82.9 50 47.6 <.0001
Ocular 79 75.2 61 58.1 .01
Epistaxis 97 92.4 98 93.3 .665
Gastrointestinal 99 94.3 93 88.6 .148
Urinary 99 94.3 96 91.4 .39
Pulmonary 91 86.7 88 83.8 .456
Intracranial 105 100 104 99 .989
Total DOGiBAT 31 29.5 11 10.5 <.0001
Values for sites significantly affected by training (P< .05) are in bolded
text. Total DOGiBAT score (bottom row) was considered correct if each
anatomic site was graded correctly, resulting in the correct total for the
individual case.
FIGURE 3 Box plots of platelet counts (A) and DOGiBAT scores (B) on admission in all dogs, dogs with PI, SI, and NI thrombocytopenia. In
each case, the box represents the interquartile range, the horizontal line represents the median, and the whiskers represent the data range.
*P5 .034; †P5 .003; ‡P5 .021; §P5 .01
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Figure 4) and when only evaluating PI dogs (rs520.476, P< .0001).
This significant negative correlation also persisted when only DOGiBAT
scores from days when platelet counts <30,000/lL were evaluated,
both in all enrolled dogs (rs520.435, P< .0001) and in only the PI
dogs (rs520.319, P5 .001).
Outcome measures (administration of blood products, duration of
hospitalization in days, and survival to discharge) were assessed in PI
dogs and compared with non-PI (SI and NI) dogs (Table 3). A total of 36
units of blood products was administered (32/36 [88.9%] to PI dogs),
with packed red blood cells (31/36 [86.1%]) being the most common
type of blood product administered. Thirteen of the 34 PI dogs (38.2%)
received blood products during hospitalization, compared with 2/27
non-PI dogs (7.4%). A significant difference was found in transfusion
requirements between PI dogs and non-PI dogs (P5 .007). Duration of
hospitalization was similar between PI dogs (median, 4.5; range, 1–12
days) and non-PI dogs (median, 4; range, 0–11 days; P5 .974). Simi-
larly, survival to discharge was similar between PI dogs (31/34 [91.2%]
survival) and non-PI dogs (25/27 [92.6%] survival; P5 .999). Of the 5
dogs that did not survive to discharge, 1 (a PI dog) died during hospital-
ization, and 4 (2 PI dogs and 2 NI dogs) were euthanized, with the rea-
son for euthanasia attributed to poor prognosis.
The correlation between outcome measures and DOGiBAT and
platelet count for all dogs and for the PI subgroup analyzed separately
is presented in Table 4. In all enrolled dogs, total DOGiBAT score at
admission was significantly correlated with blood product administra-
tion (rs50.512, P< .0001) and duration of hospitalization (rs50.35,
P5 .006). These associations persisted when only PI dogs were eval-
uated (blood product administration [rs50.541, P5 .001], duration of
hospitalization [rs50.452, P5 .007]). Total DOGiBAT score at admis-
sion was not significantly correlated with survival to discharge in all
dogs (rs520.168, P5 .197) or in only PI dogs (rs520.123, P5 .49).
A significant negative correlation was detected in all dogs between
admission platelet count and blood product administration
(rs520.355, P5 .005), but not the duration of hospitalization
(rs520.224, P5 .085) or survival to discharge (rs520.192, P5 .142).
However, when only PI dogs were evaluated, admission platelet count
was not significantly correlated with blood product administration
(rs520.248, P5 .164), duration of hospitalization (rs520.231,
P5 .196), or survival to discharge (rs520.283, P5 .111). Correlations
between outcomes and individual DOGiBAT anatomic sites are pro-
vided in the Supporting Information (Tables S1 and S2).
4 | DISCUSSION
We developed and evaluated the DOGiBAT, an assessment tool to
quantify clinical bleeding in dogs with ITP. The DOGiBAT was first
evaluated by use of a case-based quiz administered to clinicians, tech-
nicians, and veterinary students. Clinicians and technicians correctly
applied the DOGiBAT to the case-based quiz with excellent interuser
agreement, scoring all answers correctly after receiving training. The
training course was shown to improve correct implementation of the
DOGiBAT, because veterinary students randomized to receive training
before the quiz had significantly higher odds of answering correctly
compared to veterinary students randomized to take the quiz without
prior training. The final phase of this project was a preliminary evalua-
tion of application of the DOGiBAT by trained clinicians to thrombocy-
topenic dogs. The potential biological relevance of the DOGiBAT is
suggested by its inverse correlation with platelet count. In dogs with
primary ITP, admission platelet count was not correlated with any of
the evaluated outcome measures (blood product administration, dura-
tion of hospitalization, and survival to discharge), supporting the idea
that platelet count alone does not consistently predict clinical bleeding
in dogs with ITP. However, total DOGiBAT score at admission was sig-
nificantly correlated with blood product administration and duration of
FIGURE 4 Relationship between total DOGiBAT score and
platelet count in all dogs on days of hospitalization where both a
platelet count and DOGiBAT score were performed. There was a
strong negative correlation between platelet count and DOGiBAT
score in all dogs (rs520.527, P< .0001)
TABLE 3 Dogs with PI thrombocytopenia (PI) and non-PI dogs (dogs with either SI thrombocytopenia or nonimmune thrombocytopenia)
were assessed for outcome measures
PI dogs (n534) Non-PI dogs (n527)
Outcome measure #/34 % #/27 % P-value
Blood product administration 13 38.2 2 7.4 .007
Survival to discharge 31 91.2 25 92.6 .999
Outcome measure Median Range Median Range P-value
Hospitalization duration (days) 4.5 1–12 4 0–11 .974
Numbers and percentages of dogs that received blood products during hospitalization and that survived to discharge are presented, along with hospital
duration (median and range; days). Values for outcomes that are significantly different between PI and non-PI dogs (P< .05) are in bolded text.
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hospitalization in dogs with primary ITP, demonstrating its potential
prognostic value.
Immune thrombocytopenia is a common cause of severe thrombo-
cytopenia in dogs, yet individuals with similar platelet counts display
variable bleeding tendencies. The exact mechanisms for this bleeding
heterogeneity have yet to be determined. Mechanisms proposed in the
human literature include differences in platelet activation,17 interfer-
ence of antibodies with platelet function,18,19 effects of anemia on pla-
telet function, vascular endothelial abnormalities,20 and presence of
procoagulant microparticles.21,22 Clinical trials in ITP patients, there-
fore, require not only assessment of platelet count but also a metric of
bleeding severity in order to consistently gauge disease severity and
response to treatment.
We therefore developed the DOGiBAT as an objective system for
scoring clinical bleeding in dogs with ITP. To our knowledge, only 1
prior bleeding score has been reported in the veterinary literature. It
was used to score thrombocytopenic dogs in a clinical trial evaluating
efficacy of various platelet transfusions, but the scoring system itself
did not undergo thorough evaluation in that study.23 Several bleeding
scores are used to quantify bleeding in human ITP patients. The DOGi-
BAT was modeled after the ITP Bleeding Scale (IBLS), a simple yet com-
plete scoring system utilized in the human literature.5 In 1 study of
humans with ITP, the IBLS was reported to be associated with platelet
count, but this association did not persist for patients with platelet
counts<30,000/lL,5 likely because of the heterogeneity in clinical
bleeding seen with severe thrombocytopenia. Since the initial descrip-
tion of the IBLS, several other publications in the human literature have
implemented this bleeding score in ITP patients to make correlations
between clinical bleeding severity and clinicopathologic variables24–26
and to assess clinical bleeding in treatment trials.27,28
Although similar to the IBLS, several modifications tailor the DOGi-
BAT to ITP in dogs. First, the DOGiBAT does not include grading of
historical bleeding, as many canine ITP patients present with acute dis-
ease without a prior diagnosis of ITP. Similarly, grading of gynecological
bleeding was not included, because the majority of female dogs diag-
nosed with ITP are spayed.4,6,8,29 Modifications were made to the oral
cavity category, because dogs do not typically develop the blood blis-
ters commonly seen in humans with ITP. Finally, a category was added
to the DOGiBAT to account for bleeding after a minimally invasive pro-
cedure (eg, venipuncture).
The DOGiBAT was first evaluated with clinicians and technicians
in referral practices by use of a case-based quiz utilizing details and
images from clinical cases. These clinicians and technicians scored all
cases correctly at all sites, demonstrating that the DOGiBAT was easy
to employ correctly and consistently. Because the majority of clinicians
given the case-based quiz after training were either board-certified
specialists or residents receiving training in a small animal specialty, this
population is likely representative of a referral institution, but may not
represent the population of small animal veterinary practitioners as a
whole. Further evaluation in a larger population of clinicians in all types
of veterinary practices should be considered in future studies using the
DOGiBAT.
The training module instructed users on implementation of the
DOGiBAT scoring tool. To evaluate the effects of training, veterinary
students were utilized as a large population of individuals who likely
had less clinical experience than the clinicians in phase 1. Although stu-
dents were not questioned or selected based on their clinical expertise,
it is likely that the students varied in their prior exposure to small ani-
mal practice. However, students were randomized to receive the train-
ing module before taking the quiz to minimize any confounding effect
of prior experience.
We found that students who received training scored more correct
responses than those who had received no training. Scoring of 3 ana-
tomic sites (oral cavity, ocular, and cutaneous) was most improved by
having access to training. Because some bleeding grades are inherently
easier to understand without training (eg, presence or absence of epis-
taxis) or require more diagnostic acumen (eg, funduscopic bleeding or
hyphema), differences among categories were not unexpected. By pro-
viding the user a written definition and pictorial example of each bleed-
ing grade at each anatomic site, the training course was able to clarify
grading to improve correct scoring at challenging anatomic sites. We
also determined that fourth year veterinary students scored more
responses correctly compared with third year veterinary students, inde-
pendent of their access to the training course. This observation is sus-
pected to be a result of the clinical experience that fourth year
veterinary students gain from their clinical rotations during their senior
year. Although evaluated in a group of students, the training course will
likely improve correct implementation of the DOGiBAT among more
experienced clinicians as well.
In the third phase of this study, clinicians implemented the DOGi-
BAT in clinical practice in a pilot study of dogs with thrombocytopenia.
Although the DOGiBAT was developed for use in canine ITP patients,
dogs with thrombocytopenia of any underlying etiology were enrolled
and we performed comparisons of bleed scores and platelet counts
TABLE 4 Correlation data between clinical outcomes and admission DOGiBAT scores and between clinical outcomes and admission platelet
counts in all enrolled dogs (n561) and in dogs with PI thrombocytopenia (PI; n534)
All enrolled dogs (n5 61) PI dogs only (n5 34)
Platelet count Total DOGiBAT Platelet count Total DOGiBAT
Outcome measure rs P-value rs P-value rs P-value rs P-value
Blood product administration 20.355 .005 0.512 <.0001 20.248 .164 0.541 .001
Hospitalization duration (days) 20.224 .085 0.35 .006 20.231 .196 0.452 .007
Survival to discharge 20.192 .142 20.168 .197 20.283 .111 20.123 .49
Spearman correlation coefficients (rs) and P-values considered significant (P< .05) are in bolded text.
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among all dogs and specifically for the target ITP population. Because
this study represents the initial evaluation of the DOGiBAT scoring sys-
tem, dogs were excluded if they had received >48 hours of treatment
with glucocorticoids or if they had received treatment with additional
immunosuppressants, in an attempt to enroll a relatively homogeneous
population of treatment naïve dogs.
Most reports of ITP in human patients30,31 describe an inverse cor-
relation between bleed score and platelet count (ie, a lower platelet
count is associated with a higher bleed score). Similarly, we found that
dogs with primary ITP demonstrate this inverse relationship, with lower
platelet counts and higher DOGiBAT scores than those with secondary
ITP and thrombocytopenia of other causes (Figure 3). Unlike 1 study of
ITP implementing the IBLS score5 on which the DOGiBAT was mod-
eled, we found that the inverse correlation between DOGiBAT and pla-
telet count persisted for dogs with counts <30,000/lL. Possible
reasons for this observation include differences between the 2 studies
in their design, patient populations, and the statistical methods used to
determine association. The population reported previously consisted of
human patients primarily with chronic ITP, enrolled at any visit regard-
less of platelet count and treatment status.5 To be enrolled in our
study, dogs had to have platelet counts <50,000/lL and could not
have been receiving glucocorticoids for>48 hours before enrollment.
Therefore, our population was more likely to have acute clinical dis-
ease. Additional studies with well-defined canine and human popula-
tions are needed to further assess the relationship between severity of
bleeding and platelet count in both species.
When assessing outcome measures in dogs with primary ITP, we
found no association between platelet count at admission and blood
product administration, survival to discharge, or duration of hospitaliza-
tion, similar to results of a previous retrospective study of prognostic
factors in ITP.4 However, there was a significant correlation between
admission DOGiBAT score and both blood product administration and
duration of hospitalization (ie, PI dogs with higher DOGiBAT scores at
admission were more likely to receive blood products and have a lon-
ger duration of hospitalization). Therefore, the DOGiBAT may have
potential as a metric of disease severity in dogs with ITP. Reasons that
platelet count did not correlate with outcome measures could include
other concurrent patient factors such as differences in vascular integ-
rity, differences in autoantibody effect on platelet function, and differ-
ence in activation state of the patient’s remaining platelets. The fact
that platelet count did not correlate with any of the outcome measures
examined in PI dogs highlights the importance of a bleeding severity
scoring system such as DOGiBAT. Further evaluation in a larger popu-
lation of dogs with primary ITP is needed to confirm this preliminary
finding.
Our study had some limitations. First, the training and evaluation
of clinicians’ DOGiBAT scoring used digital case-based materials, rather
than physical examination of clinical patients. However, this design
allowed for a consistent method of assessing correct implementation
of the DOGiBAT across multiple institutions. Future studies could
include on-site clinician assessment of clinical patients to further com-
pare interuser agreement at a single institution.
An inherent feature of the DOGiBAT scoring system is that the
total score may not be predictive of morbidity or mortality because
hemorrhage at each anatomic site is not equivalent. For example,
intracranial hemorrhage is 1 of the most severe clinical sequela of
ITP. Melena has been shown to be a negative survival predictor in
dogs with ITP,4 and thus a gastrointestinal bleed score of 2 may
have more clinical relevance than a cutaneous bleed score of 2. A
truly summative score would be ideal, but would require assigning a
“severity factor” to each site. In the absence of large follow-up stud-
ies with extensive outcome data, it would be premature to assign
such severity factors to the DOGiBAT. Additionally, although the
correlation of DOGiBAT scores with outcome measures in ITP dogs
may demonstrate its potential prognostic value, this could be the
result of a type 1 error (ie, the reporting of a significant relationship
when 1 does not actually exist). The relationship between DOGiBAT
score and outcome requires further evaluation and validation in
additional studies of thrombocytopenic dogs. Additionally, our
results do not provide cut-off values predictive of transfusion
requirements or duration of hospitalization.
In conclusion, we have developed the DOGiBAT, a bleed score
system that can be used to score canine patients with thrombocytope-
nia. Adoption of the DOGiBAT scoring system and training course as a
component of disease severity assessment may help facilitate future
multi-institution clinical studies of dogs with ITP. Monitoring DOGiBAT
scores could be included with other clinicopathologic variables in future
studies with the goal of identifying predictors of disease severity and
response to treatment and investigating the reasons why ITP patients
have variable bleeding tendencies.
WORK PERFORMANCE SITES
Clinical cases were enrolled at Iowa State University (ISU), Cornell Uni-
versity Hospital for Animals (CUHA), Cornell University Veterinary Spe-
cialists (CUVS), and Veterinary Specialists and Emergency Services,
Rochester, NY (VSES). Clinicians and technicians at these institutions
participated in the quiz. Student volunteers from ISU participated in
the quiz and evaluation of the training course.
This study was presented as an oral abstract at the 2016 ACVIM
Forum, Denver, CO.
ACKNOWLEDGMENTS
The authors thank the clinicians at ISU, CUHA, CUVS, and VSES
for enrolling and scoring clinical cases. The authors also thank the
clinicians, technicians, and students who participated in the train-
ing and the quiz, and Amy Molitaris for assistance in compiling
clinical data. Clinical cases were enrolled as part of a larger study
of canine immune thrombocytopenia that was supported by a
grant from the American Kennel Club Canine Health Foundation
(2052). The contents of this publication are solely the responsibil-
ity of the authors’ and do not necessarily represent the views of
the Foundation.
8 | Journal of Veterinary Internal Medicine MAKIELSKI ET AL.
CONFLICT OF INTEREST DECLARATION
The authors declare that they have no conflict of interest with the
contents of this article.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
(IACUC) OR OTHER APPROVAL DECLARATION
In phase 2, veterinary student volunteers were administered a case-
based quiz. This study was considered exempt by the ISU Institu-
tional Review Board.
In phase 3, clinical cases of thrombocytopenia were enrolled with
client consent. This study was approved by the Institutional Animal
Care and Use Committees of ISU and CUHA.
ORCID
Kelly M. Makielski http://orcid.org/0000-0001-7878-2370
Dana N. LeVine https://orcid.org/0000-0002-1089-5640
REFERENCES
[1] Botsch V, Kuchenhoff H, Hartmann K, Hirschberger J. Retrospective
study of 871 dogs with thrombocytopenia. Vet Rec. 2009;164:
647–651.
[2] McMillan R. Antiplatelet antibodies in chronic immune thrombocy-
topenia and their role in platelet destruction and defective platelet
production. Hematol Oncol Clin North Am. 2009;23:1163–1175.
[3] Lewis DC, Meyers KM. Canine idiopathic thrombocytopenic pur-
pura. J Vet Intern Med. 1996;10:207–218.
[4] O’Marra SK, Delaforcade AM, Shaw SP. Treatment and predictors
of outcome in dogs with immune-mediated thrombocytopenia. J Am
Vet Med Assoc. 2011;238:346–352.
[5] Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic
purpura (ITP) bleeding score: assessment of bleeding in patients
with ITP. Br J Haematol. 2007;138:245–248.
[6] Balog K, Huang AA, Sum SO, Moore GE, Thompson C, Scott-
Moncrieff JC. A prospective randomized clinical trial of vincristine
versus human intravenous immunoglobulin for acute adjunctive
management of presumptive primary immune-mediated thrombocy-
topenia in dogs. J Vet Intern Med. 2013;27:536–541.
[7] Putsche JC, Kohn B. Primary immune-mediated thrombocytopenia
in 30 dogs (1997–2003). J Am Anim Hosp Assoc. 2008;44:250–257.
[8] Bianco D, Armstrong PJ, Washabau RJ. A prospective, randomized,
double-blinded, placebo-controlled study of human intravenous
immunoglobulin for the acute management of presumptive primary
immune-mediated thrombocytopenia in dogs. J Vet Intern Med.
2009;23:1071–1078.
[9] Rozanski EA, Callan MB, Hughes D, Sanders N, Giger U. Comparison
of platelet count recovery with use of vincristine and prednisone
or prednisone alone for treatment for severe immune-mediated
thrombocytopenia in dogs. J Am Vet Med Assoc. 2002;220:
477–481.
[10] Boston SE, Moens NM, Kruth SA, Southorn EP. Endoscopic evalua-
tion of the gastroduodenal mucosa to determine the safety of
short-term concurrent administration of meloxicam and dexametha-
sone in healthy dogs. Am J Vet Res. 2003;64:1369–1375.
[11] Wallisch K, Trepanier LA. Incidence, timing, and risk factors of
azathioprine hepatotoxicosis in dogs. J Vet Intern Med. 2015;29:
513–518.
[12] Pritchard JC, Jacob ME, Ward TJ, Parsons CT, Kathariou S, Wood
MW. Listeria monocytogenes septicemia in an immunocompromised
dog. Vet Clin Pathol. 2016;45:254–259.
[13] Smith PM, Haughland SP, Jeffery ND. Brain abscess in a dog immu-
nosuppressed using cyclosporin. Vet J. 2007;173:675–678.
[14] Siak MK, Burrows AK. Cutaneous nocardiosis in two dogs receiving
ciclosporin therapy for the management of canine atopic dermatitis.
Vet Dermatol. 2013;24:453–456. e102–453.
[15] O’Marra SK, Shaw SP, deLaforcade AM. Investigating hypercoa-
gulability during treatment for immune-mediated thrombocytope-
nia: a pilot study. J Vet Emerg Crit Care (San Antonio) 2012;22:
126–130.
[16] Bachman DE, Forman MA, Hostutler RA, Corn S, Lin J, Kociba GJ.
Prospective diagnostic accuracy evaluation and clinical utilization of
a modified assay for platelet-associated immunoglobulin in throm-
bocytopenic and nonthrombocytopenic dogs. Vet Clin Pathol. 2015;
44:355–368.
[17] Panzer S, Rieger M, Vormittag R, Eichelberger B, Dunkler D,
Pabinger I. Platelet function to estimate the bleeding risk in auto-
immune thrombocytopenia. Eur J Clin Invest. 2007;37:814–819.
[18] Chu XX, Hou M, Peng J, et al. Effects of IgG and its F(ab’)2 frag-
ments of some patients with idiopathic thrombocytopenic purpura
on platelet aggregation. Eur J Haematol. 2006;76:153–159.
[19] Olsson A, Andersson PO, Tengborn L, Wadenvik H. Serum from
patients with chronic idiopathic thrombocytopenic purpura fre-
quently affect the platelet function. Thromb Res. 2002;107:
135–139.
[20] Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hem-
orrhage in thrombocytopenia. Blood. 2008;111:4958–4964.
[21] Tantawy AA, Matter RM, Hamed AA, Shams El Din El Telbany MA
Platelet microparticles in immune thrombocytopenic purpura in
pediatrics. Pediatr Hematol Oncol. 2010;27:283–296.
[22] Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet
microparticles in autoimmune thrombocytopenias. J Lab Clin Med.
1992;119:334–345.
[23] Davidow EB, Brainard B, Martin LG, et al. Use of fresh platelet con-
centrate or lyophilized platelets in thrombocytopenic dogs with clin-
ical signs of hemorrhage: a preliminary trial in 37 dogs. J Vet Emerg
Crit Care (San Antonio). 2012;22:116–125.
[24] Greene LA, Chen S, Seery C, Imahiyerobo AM, Bussel JB. Beyond
the platelet count: immature platelet fraction and thromboelastome-
try correlate with bleeding in patients with immune thrombocytope-
nia. Br J Haematol. 2014;166:592–600.
[25] Goette NP, Glembotsky AC, Lev PR, et al. Platelet apoptosis in
adult immune thrombocytopenia: insights into the mechanism of
damage triggered by auto-antibodies. PLoS One. 2016;11:e0160563.
[26] Psaila B, Bussel JB, Frelinger AL, Michelson AD. Differences
in platelet function in patients with acute myeloid leukemia and
myelodysplasia compared to equally thrombocytopenic patients
with immune thrombocytopenia. J Thromb Haemost. 2011;9:
2302–2310.
[27] Liebman HA, Saleh MN, Bussel JB, et al. Comparison of two dosing
schedules for subcutaneous injections of low-dose anti-CD20 veltu-
zumab in relapsed immune thrombocytopenia. Haematologica. 2016;
101:1327–1332.
MAKIELSKI ET AL. Journal of Veterinary Internal Medicine | 9
[28] Zeller MP, Heddle NM, Kelton JG, et al. Effect of a thrombopoietin
receptor agonist on use of intravenous immune globulin in patients
with immune thrombocytopenia. Transfusion. 2016;56:73–79.
[29] Huang AA, Moore GE, Scott-Moncrieff JC. Idiopathic immune-
mediated thrombocytopenia and recent vaccination in dogs. J Vet
Intern Med. 2012;26:142–148.
[30] Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in
adults and children with primary immune thrombocytopenia: a sys-
tematic review. J Thromb Haemost. 2015;13:457–464.
[31] Frelinger AL III, Grace RF, Gerrits AJ, et al. Platelet function tests,
independent of platelet count, are associated with bleeding severity
in ITP. Blood. 2015;126:873–879.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
Figure S1. Complete training course for correct implementation of
the canine daily bleeding score assessment tool, DOGiBAT.
Figure S2. Complete case-based quiz utilized to assess correct
implementation of the canine daily bleeding score assessment tool,
DOGiBAT.
Figure S3. Score sheet to record answers of the DOGiBAT quiz.
Figure S4. Answer key for the DOGiBAT quiz.
Figure S5. Score sheet to record daily bleeding scores for clinical
cases of ITP using the DOGiBAT.
Table S1. Correlation data between clinical outcomes and admission
DOGiBAT scores at individual anatomic sites in all enrolled dogs (n
5 61). Spearman correlation coefficients (rs) and p-values considered
significant (p < 0.05) are in bolded text.
Table S2. Correlation data between clinical outcomes and admission
DOGiBAT scores at individual anatomic sites in only dogs catego-
rized as having primary immune thrombocytopenia (n 5 34). Spear-
man correlation coefficients (rs) and p-values considered significant
(p< 0.05) in bolded text.
How to cite this article: Makielski KM, Brooks MB, Wang C,
Cullen JN, O’Connor AM, LeVine DN. Development and imple-
mentation of a novel immune thrombocytopenia bleeding score
for dogs. J Vet Intern Med. 2018;00:1–10. https://doi.org/
10.1111/jvim.15089
10 | Journal of Veterinary Internal Medicine MAKIELSKI ET AL.
